Detailed phenotyping of Tbr1‐2A‐CreER knock‐in mice demonstrates significant impacts on TBR1 protein levels and axon development
Autism Research · 2025
DOI: 10.1002/aur.3271 ↗At a glance
Journal article in Autism Research, 2025. Written by Marissa Co and 3 co-authors. Institution: Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA. Major MEDLINE topics: Axons, DNA-Binding Proteins. Cited 2 times so far (Crossref); 54 references. The full text is freely available in PubMed Central. Funded by: OHSU Richard & Marilyn Jones Endowed Fund for Advancement in Autism Research, NCATS NIH HHS, NIMH NIH HHS.
Abstract (original language)
Cre recombinase knock‐in mouse lines have served as invaluable genetic tools for understanding key developmental processes altered in autism. However, insertion of exogenous DNA into the genome can have unintended effects on local gene regulation or protein function that must be carefully considered. Here, we analyze a recently generated Tbr1‐2A‐CreER knock‐in mouse line, where a 2A‐CreER cassette was inserted in‐frame before the stop codon of the transcription factor gene Tbr1 . Heterozygous TBR1 mutations in humans and mice are known to cause autism or autism‐like behavioral phenotypes accompanied by structural brain malformations, most frequently a reduction of the anterior commissure (AC). Thus, it is critical for modified versions of Tbr1 to exhibit true wild‐type‐like activity. We evaluated the Tbr1‐2A‐CreER allele for its potential impact on Tbr1 function and complementation to Tbr1 loss‐of‐function alleles. In mice with one copy of the Tbr1‐2A‐CreER allele, we identified reduction of TBR1 protein in early postnatal cortex along with thinning of the AC, suggesting hypersensitivity of this structure to TBR1 dosage. Comparing Tbr1‐2A‐CreER and Tbr1 ‐null mice to Tbr1 ‐null complementation crosses showed reductions of TBR1 dosage ranging from 20% to 100%. Using six combinatorial genotypes, we found that moderate to severe TBR1 reductions (≥44%) were associated with cortical layer 5 expansion, while only the complete absence of TBR1 was associated with reeler ‐like “inverted” cortical layering. In total, these results strongly support the conclusion that Tbr1‐2A‐CreER is a hypomorphic allele. We advise caution when interpreting experiments using this allele, considering the sensitivity of various corticogenic processes to TBR1 dosage and the association of heterozygous TBR1 mutations with complex neurodevelopmental disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
- Vollum Institute, Oregon Health & Science University, Portland, Oregon, USA.
ORCID profiles: Marissa Co
Funding
- OHSU Richard & Marilyn Jones Endowed Fund for Advancement in Autism Research
- NCATS NIH HHS
- NIMH NIH HHS
- Collins Medical Trust
- OHSU Brain Institute Neuroscience Campaign Fund to Support Brain Health Across the Lifespan
- MRF
- MRF_
- National Institute of Mental Health
Cite
APA
Co, M., O'Brien, G. K., Wright, K. M., & O'Roak, B. J. (2025). Detailed phenotyping of Tbr1‐2A‐CreER knock‐in mice demonstrates significant impacts on TBR1 protein levels and axon development. Autism Research. https://doi.org/10.1002/aur.3271
Vancouver
Co M, O'Brien GK, Wright KM, O'Roak BJ. Detailed phenotyping of Tbr1‐2A‐CreER knock‐in mice demonstrates significant impacts on TBR1 protein levels and axon development. Autism Research. 2025. doi:10.1002/aur.3271
BibTeX
@article{Co2025,
author = {Co, Marissa and O'Brien, Grace K and Wright, Kevin M and O'Roak, Brian J},
title = {Detailed phenotyping of Tbr1‐2A‐CreER knock‐in mice demonstrates significant impacts on TBR1 protein levels and axon development},
journal = {Autism Research},
year = {2025},
doi = {10.1002/aur.3271}
}
EUVIMED